Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | ECE1 | P42892 | 2/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isovaleramide SCHEMBL9641 | 0.91 | — | — | |
| Isovaleramide SCHEMBL6055503 | 0.91 | ALDH1A1 (0.53) | ALDH1A1TDP1CA2TSHRECE1 | |
| Isovaleramide SCHEMBL28163028 | 0.88 | — | — | |
| Isovaleramide SCHEMBL7081542 | 0.88 | — | — | |
| Isovaleramide SCHEMBL1650316 | 0.88 | — | — | |
| Isovaleramide SCHEMBL9846971 | 0.88 | — | — | |
| Isovaleramide SCHEMBL28666959 | 0.86 | ALDH1A1 (0.48) | ALDH1A1TDP1CA2TSHRECE1 | |
| Isovaleramide SCHEMBL28192598 | 0.83 | ALDH1A1 (0.46) | ALDH1A1TDP1CA2ECE1CACNA2D1 | |
| Isovaleramide SCHEMBL9271798 | 0.83 | ALDH1A1 (0.46) | ALDH1A1TDP1CA2ECE1CACNA2D1 | |
| Isovaleramide SCHEMBL28439595 | 0.83 | ALDH1A1 (0.52) | ALDH1A1TDP1CA2TSHRECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10322209-B2 | Polyurethanes for osteoimplants | WARSAW ORTHOPEDIC, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| CN-104323981-B | The quick foundation and/or termination of basic steady-state drug delivery | 精达制药公司 | 2019-03-12 | — | — | CN | disclosed |
| US-20180250442-A1 | POLYURETHANES FOR OSTEOIMPLANTS | WARSAW ORTHOPEDIC INC (US) | 2018-09-06 | — | — | US | disclosed |
| EP-1434608-B1 | IMPROVED BONE GRAFT | WARSAW ORTHOPEDIC INC (US) | 2018-08-22 | — | — | EP | disclosed |
| US-9993579-B2 | Polyurethanes for osteoimplants | WARSAW ORTHOPEDIC, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| CN-107638562-A | The quick foundation and/or termination of basic steady-state drug delivery | 精达制药公司 | 2018-01-30 | — | — | CN | disclosed |
| CN-102686741-B | Rapid establishment and/or termination of substantial steady-state drug delivery | 精达制药公司 | 2018-01-19 | — | — | CN | disclosed |
| US-20170304496-A1 | POLYURETHANES FOR OSTEOIMPLANTS | WARSAW ORTHOPEDIC INC (US) | 2017-10-26 | — | — | US | disclosed |
| US-9789223-B2 | Polyurethanes for osteoimplants | WARSAW ORTHOPEDIC, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170240698-A1 | Biodegradable Stealth Polymeric Particles Fabricated Using The Macromonomer Approach By Free Radical Dispersion Polymerization | HOWARD UNIVERSITY (US) | 2017-08-24 | — | — | US | disclosed |
| CN-1103316-A | Cyclodextrin and polymer based drug delivery system | INSITE VISION INC (US) | 1995-06-07 | — | — | CN | disclosed |
| CN-1094610-A | Bioerodible controlled delivery system | INSITE VISION INC (US) | 1994-11-09 | — | — | CN | disclosed |
| CN-1094643-A | Plastifying bioerodible controlled delivery system | INSITE VISION INC (US) | 1994-11-09 | — | — | CN | disclosed |
| EP-0584220-A1 | ENGINEERING THE LOCAL INFLAMMATORY RESPONSE AS A MEANS OF CONTROLLED RELEASE DRUG DELIVERY | ENDOCON, INC. (US) | 1994-03-02 | — | — | EP | disclosed |
| CN-1081877-A | Spheronization process with charged resins | MERCK & CO INC (US) | 1994-02-16 | — | — | CN | disclosed |
| WO-1993023012-A1 | LIQUID-CONTAINING DRUG DELIVERY SYSTEM | ENDOCON, INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| CN-1074368-A | The dispersion conveying solid substance dosage form of controlled release medicine | MERCK & CO INC (US) | 1993-07-21 | — | — | CN | disclosed |
| WO-1992020325-A1 | ENGINEERING THE LOCAL INFLAMMATORY RESPONSE AS A MEANS OF CONTROLLED RELEASE DRUG DELIVERY | ENDOCON, INC. (US) | 1992-11-26 | — | — | WO | disclosed |
| US-4814183-A | Device for the controlled release of drugs with Donnan-like modulation by charged insoluble resins | MERCK & CO., INC. (US) | 1989-03-21 | — | — | US | disclosed |
| EP-0302693-A2 | Device for the controlled release of drugs with donnanlike modulation by charged insoluble resins | MERCK & CO. INC. (US) | 1989-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240698-A1 | Biodegradable Stealth Polymeric Particles Fabricated Using The Macromonomer Approach By Free Radical Dispersion Polymerization | LDHA, LDHB, ALDH2 | ALDH1A1 7/4885TDP1 2592/4885CA2 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.